125 related articles for article (PubMed ID: 21803623)
1. Potential interaction of natural dietary bioactive compounds with COX-2.
Maldonado-Rojas W; Olivero-Verbel J
J Mol Graph Model; 2011 Sep; 30():157-66. PubMed ID: 21803623
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel pyrazole compounds.
Youssef AM; Neeland EG; Villanueva EB; White MS; El-Ashmawy IM; Patrick B; Klegeris A; Abd-El-Aziz AS
Bioorg Med Chem; 2010 Aug; 18(15):5685-96. PubMed ID: 20609589
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking studies of novel palmitoyl-ligands for cyclooxygenase-2.
Bhagavat R; Saqib A; Karigar C
Chem Biol Drug Des; 2012 Jun; 79(6):1043-8. PubMed ID: 22339889
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.
Qiu KM; Yan R; Xing M; Wang HH; Cui HE; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Nov; 20(22):6648-54. PubMed ID: 23062711
[TBL] [Abstract][Full Text] [Related]
6. Screening of curcumin-derived isoxazole, pyrazoles, and pyrimidines for their anti-inflammatory, antinociceptive, and cyclooxygenase-2 inhibition.
Ahmed M; Qadir MA; Hameed A; Imran M; Muddassar M
Chem Biol Drug Des; 2018 Jan; 91(1):338-343. PubMed ID: 28741789
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.
Fioravanti R; Bolasco A; Manna F; Rossi F; Orallo F; Ortuso F; Alcaro S; Cirilli R
Eur J Med Chem; 2010 Dec; 45(12):6135-8. PubMed ID: 20974503
[TBL] [Abstract][Full Text] [Related]
9. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.
Al-Suwaidan IA; Alanazi AM; El-Azab AS; Al-Obaid AM; ElTahir KE; Maarouf AR; Abu El-Enin MA; Abdel-Aziz AA
Bioorg Med Chem Lett; 2013 May; 23(9):2601-5. PubMed ID: 23528298
[TBL] [Abstract][Full Text] [Related]
10. The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.
Shukla S; Bafna K; Sundar D; Thorat SS
PLoS One; 2014; 9(6):e90637. PubMed ID: 24603686
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
12. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Cerchietti LC; Navigante AH; Castro MA
Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.
Ahlström MM; Ridderström M; Zamora I; Luthman K
J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, anti-inflammatory activity and molecular docking studies of 2,5-diarylfuran amino acid derivatives.
Stefani HA; Botteselle GV; Zukerman-Schpector J; Caracelli I; da Silva Corrêa D; Farsky SH; Machado ID; Santin JR; Hebeda CB
Eur J Med Chem; 2012 Jan; 47(1):52-8. PubMed ID: 22071254
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking studies of withanolides against Cox-2 enzyme.
Prabhakaran Y; Dinakaran SK; Macharala SP; Ghosh S; Karanam SR; Kanthasamy N; Avasarala H
Pak J Pharm Sci; 2012 Jul; 25(3):595-8. PubMed ID: 22713947
[TBL] [Abstract][Full Text] [Related]
16. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
Zheng M; Zhang Z; Zhu W; Liu H; Luo X; Chen K; Jiang H
Bioorg Med Chem; 2006 May; 14(10):3428-37. PubMed ID: 16458008
[TBL] [Abstract][Full Text] [Related]
17. Genome wide analysis and comparative docking studies of new diaryl furan derivatives against human cyclooxygenase-2, lipoxygenase, thromboxane synthase and prostacyclin synthase enzymes involved in inflammatory pathway.
Sekhar PN; Reddy LA; De Maeyer M; Kumar KP; Srinivasulu YS; Sunitha MS; Sphoorthi IS; Jayasree G; Rao AM; Kothekar VS; Narayana PV; Kishor PB
J Mol Graph Model; 2009 Nov; 28(4):313-29. PubMed ID: 19766029
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Lu ZH; Xiong XY; Zhang BL; Lin GC; Shi YX; Liu ZG; Meng JR; Zhou YM; Mei QB
Acta Pharmacol Sin; 2005 Dec; 26(12):1505-11. PubMed ID: 16297351
[TBL] [Abstract][Full Text] [Related]
19. Coupled atomic charge selectivity for optimal ligand-charge distributions at protein binding sites.
Bhat S; Sulea T; Purisima EO
J Comput Chem; 2006 Dec; 27(16):1899-907. PubMed ID: 16988958
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.
Reddy MV; Billa VK; Pallela VR; Mallireddigari MR; Boominathan R; Gabriel JL; Reddy EP
Bioorg Med Chem; 2008 Apr; 16(7):3907-16. PubMed ID: 18272371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
